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Reduction of Ischemic K' Loss and
Glibenclamide, one of the antidiabetic sulfonylureas, is known to block ATP-dependent K' channels. We used this drug to determine to what extent K' loss from acutely ischemic myocardium is mediated via these channels. We also investigated whether glibenclamide would influence ischemic arrhythmias. Isolated rat hearts rendered globally ischemic showed no correlation between early lactate and K' efflux rates. Cumulative K' loss during 11 minutes of global ischemia (0.5 ml min' g-') was reduced, from 3.2±0.3 to 2.5±0.1 ,ieq/g (p<0.025) by 1 ,uM glibenclamide and from 3.3±0.2 to 1.9±0.2 ,ueq/g (p<0.005) by 10 ,uM glibenclamide, while lactate efflux was unaltered by the drug. Glibenclamide also exhibited potent antifibrillatory activity, abolishing irreversible ventricular fibrillation during regional ischemia (0/6 vs. 5/6 controls; p <0.02) and during global ischemia (0/7 vs. 9/9 controls; p <0.01). Heart rate, coronary flow rate, peak systolic pressure, and myocardial oxygen consumption were unaltered by the drug (1 ,uM) . Similarly, glibenclamide (1 ,M) did not alter myocardial ATP, phosphocreatine or lactate content, or glucose utilization. Ventricular fibrillation threshold during normoxia was also unaltered by glibenclamide (1 ,uM) . We conclude that K' loss during acute myocardial ischemia is mediated partly by ATP-dependent K' channels, and not by a tightly coupled co-efflux with anionic lactate. (Circulation Research 1990;66:478-485) T he loss of K' ions from myocardial tissue is an early response to the interruption of oxygenated blood flow.1,2 The mechanism of this K' efflux is uncertain, and several explanations have been proposed.3 In particular, the hypothesis that K' efflux is an ionic shift in response to electrogenic anion loss in the form of anionic lactate from ischemic tissues has enjoyed some prominence.3-5 More recently, ATP-regulated potassium channels have been demonstrated in pancreatic cells6 and isolated cardiac myocytes7,8 and may provide an alternative explanation for the increased K' conductance and efflux seen during hypoxia7,9'10 and metabolic inhibition.1" We tested the hypothesis that K' loss in acute myocardial ischemia may be partly regulated by these channels by using glibenclamide, a sulfonylurea that blocks ATP-dependent potassium channels in both pancreatic cells12'3 and cardiac myocytes. 1415 We also determined whether possible alterations in ischemic K' efflux by glibenclamide would influence ischemic arrhythmias, since the presence of extracellular K' ions is considered to be one of the important factors in the genesis of ischemic arrhythmias.16
Materials and Methods Perfusion Procedures
Normoxic perfusion. The hearts of male Long-Evans rats (250-350 g) were rapidly excised after anesthesia and were mounted on a Langendorff retrograde perfusion apparatus within 2 minutes. Hearts were then allowed to stabilize for 15 minutes. Heart rate, coronary effluent flow rate, and myocardial oxygen consumption17 were measured during normoxic perfusion. Peak left ventricular systolic pressure was measured with a transmural intraventricular PVC cannula connected to a pressure transducer (Statham model P231D, Gould, Cleveland, Ohio) and recorded on a chart recorder (Multitrace, Lectromed, St. Peter, UK). The effect of glibenclamide 1 ,uM was assessed at 10 and 20 minutes after perfusion with the drug.
Models of ischemia. A loose suture (3.0 polyester) was inserted 2 mm below the origin of the left anterior descending coronary artery and later tightened to produce an area of regional ischemia.18 Ischemic arrhythmias were then monitored for the initial 30 minutes of the ischemic period.
In a separate series of experiments, a 35-minute period of global ischemia was induced by restricting the perfusion rate to less than 10% of normal. A precalibrated low-flow peristaltic pump (Minipuls, Gilson, Villiers le Bel, France) delivered 0.5 ml g`1 min-1 oxygenated perfusate (fresh cardiac mass calculated from the body mass). Ventricular epicardial pacing via a bipolar electrode placed high on the left ventricular free wall was initiated 5 minutes before ischemia and continued throughout. Stimulus rate was 5 Hz (stimulator model S88, Grass Instruments, Quincy, Massachusetts), the duration was 2 msec, and the voltage was twice capture threshold. Coronary effluent was sampled in 2-minute intervals continuously from 1 to 16 minutes of ischemia or until the onset of fibrillation (a 1-minute delay in sampling following the onset of ischemia was instituted to allow the runoff of nonischemic effluent). In this model of global ischemia, ventricular arrhythmias are consistently observed. 19 In both models of ischemia, the epicardial electrogram was monitored on an oscilloscope (model 5110, Tektronix, Beaverton, Oregon) and recorded on magnetic tape or a chart recorder for analysis of arrhythmias.
Perfusion Media and Drugs Used
We used modified Krebs-Henseleit medium containing (in millimolars per liter) KCl 5.9, NaCl 143, NaHCO3 24.9, K2HPO4 1.2, MgSO4 1.2, CaCl2 1.25, and glucose 11, and oxygenated with 95% 02-5% CO2. K' was lowered to 3 mM in experiments involving regional ischemia for an increased incidence of ischemic arrhythmias.20 Glibenclamide (Daonil, Hoechst Pharmaceuticals, Frankfurt, FRG, and Sigma Chemical, St. Louis, Missouri) was solubilized in dimethylsulfoxide (DMSO, Sigma, solvent concentration, 0.005% vol/vol) and was added to the perfusate immediately before use. DMSO was present in control perfusions. Glibenclamide was introduced 10 minutes before coronary artery ligation in regional ischemia experiments and immediately preceding flow restriction in global ischemia experiments. Glucose utilization was measured using 2[3H]glucose (0.02 Ci/Mol) (Amersham, Wareham, UK). Quantification ofArrhythmias Ventricular fibrillation threshold was measured during normoxic perfusion according to methods previously described. 20 Briefly, a train of 10 electrical stimuli was applied within 100 msec following the T wave of the electrocardiogram. Arrhythmias during global and regional ischemia were measured using a single epicardial electrode and were characterized according to the following features: 1) Ventricular extrasystoles: Single, couplet, or triplet ventricular responses, preceded by a shortened beat-to-beat interval. 2) Ventricular tachycardia: Repetitive ventricular responses occurring at a frequency of at least twice that of sinus rhythm (universally < 15 Hz) with a recurring baseline voltage. 3) Ventricular fibrillation: Extremely rapid (usually >20 Hz) bizarre activity with no individually recognizable ventricular responses with no recurring amplitude or baseline voltage.
Arrhythmias were further categorized as "reversible," where normal sinus rhythm was regained within 3 minutes, or "irreversible," where spontaneous defibrillation did not occur. In all experiments, irreversibility occurred only in the context of ventricular fibrillation and was present for the remaining experimental period or until electrical activity declined and no epicardial activity was measurable. The duration of ischemia before the onset of ventricular fibrillation (latency time) was also noted.
Biochemical Assays
Samples of coronary effluent from globally ischemic hearts were placed on ice, and volumes were measured and then analyzed for K' and Na+ concentration using a lithium standard flame photometer (model 543, Instrumentation Laboratory, Dayton, Ohio).
Coronary effluent lactate concentration was assayed by standard enzymatic techniques2' (D07 spectrophotometer, Beckman Instruments, Fullerton, California). Glucose uptake was calculated from the coronary effluent 3H20 release derived from 2['H]glucose uptake and metabolism.22 Myocardial ATP, phosphocreatine, and lactate levels following 15 minutes of normoxic perfusion and (separately) following 10 minutes of global ischemia were determined from whole hearts freeze clamped at -196°C.21
Data Presentation and Statistical Analysis
All data are mean±+SEM unless otherwise stated.
Biochemical data are expressed as micromolars per gram fresh cardiac mass. Arrhythmias were expressed in terms of latency time, incidence ratio, and the number and duration of episodes. Lactate (IM g`min-1) and K' (,ueq g`min') efflux were expressed in terms of their increase (arteriovenous difference) in the coronary effluent of globally ischemic hearts over specified time intervals during early ischemia, and as the cumulative increase in the ischemic coronary effluent (geq/g).
Data describing K' loss (Table 1) were compared using a two-tailed t test. Cumulative increases in K'
in the coronary effluent and Y intercepts in Figure 2B (inset) were compared by analysis of variance and Dunnett's t test. Arrhythmia incidences and durations were compared using Fisher's exact test and a two-tailed t test, respectively. Statistical significance was defined atp<0.05. 
Results

Lactate and K' Loss During Ischemia
Mean rates of lactate and potassium loss from globally ischemic hearts are shown in Figure 1 . The efflux rate for lactate took longer to attain its maximum than that for K', after which it remained elevated, while that of K' declined steadily during the first 11 minutes of ischemia. There was thus no constant ratio of K'/lactate efflux rates. Regression analysis of simultaneous individual K' and lactate efflux rates showed no correlation in control (r2=0.03), or in glibenclamide (r2=0.14), perfused hearts (results not shown).
Effect of Glibenclamide on Ischemic Lactate and K' Loss
Cumulative lactate efflux during ischemia was unchanged by the addition of glibenclamide (1 ,uM) ( Figure 2A ). The increase in K' concentration (A [K']) in coronary effluent of globally ischemic hearts was maximal within the first 3 minutes of ischemia and declined progressively thereafter (Table 1) . Glibenclamide reduced the effluent A[Kt] during ischemia from as early as 2 minutes. The cumulative K' efflux ( Figure   2B ) after 10 minutes of ischemia was reduced from 3.2+0.3 to 2.5±0.1 ,ueq/g (p<0.025), and to 1.9±0.2 ,ueq/g (p<0.005) by glibenclamide (1 and 10 ,M, respectively). The data in Figure 2B describe a single exponential process. The slopes of the logarithmic transformations (inset), which give the rate constants of these exponentials (indicating the general time course of efflux from onset to steady state), were unaltered by glibenclamide. The Y intercepts (Kt-Kt0) are equivalent to the predicted maximum cumulative K' losses at steady state and were progressively reduced from 5.3±0.4 ,geq/g (control) to 3.5±0.4 ,ueq/g (p<0.005) and 2.3±0.3 ,ueq/g (p<<0.005) by 1 and 10 gM glibenclamide, respectively.
Effect of Glibenclamide on Arrhythmias
Arrhythmias during regional ischemia ( Table 2) . Following coronary artery ligation, a similar reduction in mean coronary flow rate (measured at 5-minute intervals) occurred in both groups, indicating a similar degree of ischemia. In the control experiments, the latency time to ventricular fibrillation was 15.5 ±2.9 minutes, with irreversible ventricular fibrillation occurring in most hearts. In contrast, in the presence of glibenclamide the latency time was virtually doubled, and the occurrence of irreversible ventricular fibrillation was totally prevented, with only one self-limiting episode of ventricular fibrillation of less than 30 seconds' duration occurring. Short, self-limiting episodes of ventricular tachycardia and ventricular extrasystoles occurred in all hearts: the cumulative duration of ventricular tachycardia in the presence of glibenclamide (1 ,uM) exceeded that of the controls. However, glibenclamide significantly reduced the cumulative duration of all tachyarrhythmias combined.
Arrhythmias during global ischemia (Table 3) . Irreversible ventricular fibrillation occurred in all control experiments after a latency time of 15.2±1.9 minutes of ischemia, while in hearts perfused with 1 ,M glibenclamide, ventricular fibrillation was completely eliminated. Self-limiting episodes of ventricular tachycardia of less than 10 seconds' duration and ventricular extrasystoles occurred with equivalent severity in both groups. An increased concentration of glibenclamide (10 ,uM) was found to have a similar antiarrhythmic effect in this model: irreversible ventricular fibril- 
Effect of Glibenclamide on Ventricular Fibrillation Threshold
The ventricular fibrillation threshold of normoxically perfused rat hearts was unchanged from 6.9+1.1 mA in control hearts to 8.1+1.1 mA (p=0.12) after perfusion with glibenclamide (1 ,uM; n=6).
Effect of Glibenclamide on Heart Function and Metabolism
Neither glibenclamide (1 ,M) nor the DMSO solvent had any significant effect on heart rate, coronary flow, peak left ventricular systolic pressure, or myocardial oxygen consumption during normoxic perfusion (data not shown). Glibenclamide (1 ,uM) had no effect on myocardial high-energy phosphate and lactate content either during normoxic perfusion or following 10 minutes of global ischemia ( Table 4 ). The rate of glucose utilization during normoxia and following global ischemia was also unchanged by glibenclamide (1 ,uM) ( Figure 3 ).
Discussion
Our data show that glibenclamide reduces both early K' loss as well as ischemic arrhythmias in the isolated perfused rat heart.
Model of Global Ischemia Used in Our Studies
In these experiments, two models of ischemia were used. The first was the "standard" model of introducing regional ischemia by ligation of the coronary artery.18 In addition, we have used a novel method of invoking global low-flow ischemia, where arrhythmias are observed when pacing the hearts at a relatively high rate. The coronary flow that we have used (although between 5% and 10% of that during Langendorff perfusion) is still about 50% of the flow as it occurs in situ (1-1.5 ml/min/g), and there is the possibility that the residual flow was enough to wash out all the extracellular metabolites, creating a state of hypoxia, rather than true ischemia.
We have not measured the potassium concentration with ion-sensitive electrodes in the extracellular spaces, which is a limitation of this study. However, there is reason to believe that the extracellular potassium concentration did increase outside the cell, and was not all washed away by the residual flow. In a study by Watanabe et al,23 it was found that a decrease of the coronary flow by as little as 20-25% already led to a marked accumulation of extracellular potassium. It is also of interest to note that in this study, changes of extracellular pH occurred at still relatively high flow rates; therefore, our model is one of true ischemia, rather than a state of hypoxia. Furthermore, the pattern of potassium efflux seen in our studies is characteristic of an ischemic insult of fixed severity with maintained "washout" (see Thomas et a124).
Mechanism of K' Loss During Ischemia
Can an inhibition of the Na-K pump explain K' loss during ischemia? The net loss of K' during early (first 10 minutes) ischemia can theoretically be explained either by a decreased influx or an increased efflux of K'. A decreased influx may result from an altered Na-K,ATPase activity during early ischemia.25 If intracellular sodium activity does not rise during this phase of ischemia,26 it would argue against this hypothesis.3 Using nuclear magnetic resonance, it was shown that there was an increase in intracellular sodium starting after 6-7 minutes of global ischemia in the rat heart. It seems unlikely that an inhibition of the Na-K pump was solely responsible for the early K' loss in our model of ischemia. First, changes in extracellular potassium occurred very early (first minutes of ischemia), and second, glibenclamide (which has no known effects on the Na-K pump) was able to reduce this early loss of K'. Is early ischemic potassium efflux linked to that of lactate? It has been proposed that K' is redistributed in association with electrogenic anionic lactate efflux.3-5 This hypothesis is based on proportional efflux rates of K' and lactate from progressively ischemic dog hearts2728 and a decreased H+/K' efflux ratio with maintained lactate efflux from fatigued frog sartorius muscle.29 Our data do not support this hypothesis fully, as K' and lactate efflux rates during early ischemia correlated poorly. Moreover, glibenclamide markedly reduced K' loss without effect on lactate efflux. Furthermore, alteration of extracellular K' concentration failed to influence lactate efflux during ischemia (S.C. Dennis, unpublished observation), indicating that the movements of these ions are not necessarily closely linked.
A Possible Role for ATP-Dependent Channels An increased efflux of 42K' during hypoxia and metabolic inhibition has, however, been demonstrated.9 The resulting increased K' conductance is one of the most likely mechanisms for the shortening of the action potential under such conditions.1011
The nature of this increased K' conductance has recently been demonstrated to be a class of K' channels that are regulated by intracellular triphosphate nucleotides (principally ATP).78 These potassium channels open when the cellular ATP falls and so could account for the increased K' conductance and K' efflux during hypoxia. 30 We propose that this mechanism may also operate during myocardial ischemia. The ATP-dependent K' channel is thought to have multiple closely associated regulatory binding sites31 with which sulfonylureas interact specifically12,13 and in so doing compete with triphosphate nucleotide molecules.13 Reduction in ATP-dependent K' chan- nel conductance by glibenclamide has been described in pancreatic cell membrane patches12 and in isolated cardiac myocytes (E. Carmeliet, unpublished observation). If these channels were to open during ischemia and contribute toward ischemic K' loss, then glibenclamide should reduce this loss. Our data have demonstrated such a partial reduction in ischemic K' loss ( Figure 2A ) by glibenclamide.
However, one cannot assume that all K' loss during ischemia will occur through these channels.
First, not all ischemic K' loss was blocked by glibenclamide, even at a concentration as high as 10 ,uM, which is sufficient to inhibit channel activity. Second, it is not certain that glibenclamide only affected ATP-dependent K channels; for example, metabolic effects of glibenclamide may have occurred. We have not seen any action of low concentrations of glibenclamide on intracellular high-energy phosphates or on glucose utilization, in spite of its effect to reduce ischemic K' loss and arrhythmias. We cannot, however, be sure that the higher concentration used (10 ,uM) had such effects. Furthermore, tissue concentrations of ATP in early ischemia (Table 4 ) are considerably higher than the measured half maximal concentration of ATP (Km=0.5 mM) needed to "open" the ATP-dependent K channel,7 which may make the concept of these channels opening during ischemia doubtful. However, several factors could account for this discrepancy. First, glycolytic ATP sources near to the sarcolemma may be more important than mitochondrial derived ATP in regulating the ATP-dependent K' channel conductance,32 supporting the concept of subcellular compartmentalization of energy sources. 33 Second, free ATP for hydrolysis near the sarcolemma may be several-fold lower than the measured myocardial ATP levels. 30 Third, additional regulatory factors acting on the K' channel may account for a modulated ATP sensitivity. Thus, in the presence of ADP34 and GTP35 the Km for ATP rises. The effects of changes in pH or inorganic phosphate on this channel are not known, although it is known that pH affects ischemic potassium efflux.4
K' Loss and Ischemic Arrhythmias
The exact role for potassium in ischemic arrhythmias is not fully understood. In regional ischemia, the accumulation of K' in the ischemic zone, and the associated membrane depolarization, may result in conditions of inhomogeneity and current flow across the border zone, serving as a trigger for arrhythmias.36-38 Accordingly, the bolus infusion of potassium chloride into a region of nonischemic myocardium can induce severe ventricular arrhythmias. [39] [40] [41] [42] [43] In contrast, however, the incidence of arrhythmias during myocardial ischemia may also be reduced44,45 when the arterial K' concentration is increased above physiological levels.
We found that glibenclamide reduced both K' loss and arrhythmias during ischemia, suggesting that these may be causal relations between these phenomena. Results similar to ours were very recently described by Wolleben et al,46 who found that glibenclamide and tolbutamide were able to prevent ischemia-induced arrhythmias in a rat heart model, while the K' channel activators pinacidil and cromakalin diminished the antiarrhythmic effect of glibenclamide. Furthermore, pinacidil, a drug known to activate ATP-dependent K' channels, is proarrhythmic in a canine model of sudden death. 47 If ischemic potassium loss is correlated with arrhythmias, the magnitude of the reduction in K' loss required to achieve an antiarrhythmic effect is not known. Mori et a148 have shown a higher extracellular K' activity in deep ischemic myocardium in hearts that fibrillated than in those without fibrillation. K' activity just before the onset of fibrillation in most hearts appears to have exceeded that of nonfibrillating hearts by less than 40%. We found that relatively small decrease in cumulative effluent K' by glibenclamide was associated with marked antiarrhythmic properties. However, there did not seem to be any direct relation between these measurements: an increment in glibenclamide concentration curbed ischemic K' efflux more markedly but showed no greater reduction of arrhythmias during global ischemia. We therefore support the conclusion that other mechanisms apart from those associated with K' loss play an important role in ischemic arrhythmias. 16 The apparent selective suppression of ventricular fibrillation and not of ventricular tachycardia may indicate different underlying mechanisms for these arrhythmias.
Possible Mechanisms for the Antiarrhythmic Effect of Glibenclamide We can exclude several possible mechanisms for the antiarrhythmic action of glibenclamide. First, alteration in coronary flow rate49 may cause a reduction in ischemic zone size and hence arrhythmias during regional ischemia.50 Glibenclamide did not ISCHEMIA 1~~~~~~1 / 1~~~X~~~~~ṽ 1/ affect coronary flow during normoxic perfusion, or during regional ischemia. During global ischemia the flow rate was fixed, so also here no changes could have occurred. Second, during ischemia, reduced cardiac work or enhanced metabolism may benefit myocardial survival,49 resulting in delayed cellular injury and death51 and reduced ischemic arrhythmias. Glibenclamide had no effect on cardiac work, producing no difference in myocardial oxygen consumption or cardiac rate and systolic pressure generation. Third, glibenclamide did not alter glycolytic metabolism during ischemia, causing no change in 2[3H]glucose uptake, lactate efflux, or tissue highenergy phosphate complement.
The action potential of isolated myocytes is unaltered by glibenclamide,52 suggesting an absence of effects on membrane currents during normoxia. In addition, glibenclamide failed to influence the ventricular fibrillation threshold of isolated normoxically perfused rat hearts in our experiments. A very likely mechanism for the antiarrhythmic action of glibenclamide that should be considered is a lengthening of the ischemic action potential: the decreased action potential as a result of intracellular dialysis with low ATP concentrations, or by application of DNP, can be restored by the application of glibenclamide.15 If this lengthening of the action potential by glibenclamide were to occur in ischemic tissue, the spatial inhomogeneity of potential during ischemia, and thus injury current, could be decreased. Furthermore, it is possible that there may be changes in the refractory period and thus all effects that may have antiarrhythmic consequences.
